Existing law requires certain public and private health plans, including Medicaid and health plans for state and local employees to provide coverage, in certain circumstances, for medically necessary biomarker testing for the diagnosis, treatment, appropriate management and ongoing monitoring of cancer when such biomarker testing is supported by medical evidence. (NRS 287.010, 287.04335, 422.272364, 689A.0446, 689B.0361, 695C.050, 689C.1688, 695A.1859, 695B.19087, 695C.16932, 695G.1703) This bill removes the limitations that such coverage is only required if the biomarker testing is: (1) medically necessary; and (2) for the diagnosis, treatment, appropriate management and ongoing monitoring of cancer. This bill thus requires public and private health plans to cover any biomarker testing for the diagnosis, treatment, appropriate management and ongoing management of a medical condition or disease when such biomarker testing is supported by medical evidence, regardless of whether the biomarker testing is determined to be medically necessary.

Statutes affected:
As Introduced: 689A.0446, 689B.0361, 689C.1688, 695A.1859, 695B.19087, 695C.16932, 695G.1703, 422.272364
BDR: 689A.0446, 689B.0361, 689C.1688, 695A.1859, 695B.19087, 695C.16932, 695G.1703, 422.272364